Literature DB >> 20002787

Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot.

Krishana C Gulla1, Kshitij Gupta, Anders Krarup, Peter Gal, Wilhelm J Schwaeble, Robert B Sim, C David O'Connor, Krishnan Hajela.   

Abstract

The lectin pathway of complement is activated upon binding of mannan-binding lectin (MBL) or ficolins (FCNs) to their targets. Upon recognition of targets, the MBL-and FCN-associated serine proteases (MASPs) are activated, allowing them to generate the C3 convertase C4b2a. Recent findings indicate that the MASPs also activate components of the coagulation system. We have previously shown that MASP-1 has thrombin-like activity whereby it cleaves and activates fibrinogen and factor XIII. MASP-2 has factor Xa-like activity and activates prothrombin through cleavage to form thrombin. We now report that purified L-FCN-MASPs complexes, bound from serum to N-acetylcysteine-Sepharose, or MBL-MASPs complexes, bound to mannan-agarose, generate clots when incubated with calcified plasma or purified fibrinogen and factor XIII. Plasmin digestion of the clot and analysis using anti-D-dimer antibodies revealed that the clot was made up of fibrin and was similar to that generated by thrombin in normal human plasma. Fibrinopeptides A and B (FPA and FPB, respectively) were released after fibrinogen cleavage by L-FCN-MASPs complexes captured on N-acetylcysteine-Sepharose. Studies of inhibition of fibrinopeptide release indicated that the dominant pathway for clotting catalysed by the MASPs is via MASP-2 and prothrombin activation, as hirudin, a thrombin inhibitor that does not inhibit MASP-1 and MASP-2, substantially inhibits fibrinopeptide release. In the light of their potent chemoattractant effects on neutrophil and fibroblast recruitment, the MASP-mediated release of FPA and FPB may play a role in early immune activation. Additionally, MASP-catalysed deposition and polymerization of fibrin on the surface of micro-organisms may be protective by limiting the dissemination of infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002787      PMCID: PMC2842495          DOI: 10.1111/j.1365-2567.2009.03200.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  55 in total

Review 1.  The lectin-complement pathway--its role in innate immunity and evolution.

Authors:  Teizo Fujita; Misao Matsushita; Yuichi Endo
Journal:  Immunol Rev       Date:  2004-04       Impact factor: 12.988

2.  Interaction of soybean trypsin inhibitor with thrombin and its effect on prothrombin activation.

Authors:  G F Lanchantin; J A Friedmann; D W Hart
Journal:  J Biol Chem       Date:  1969-02-10       Impact factor: 5.157

Review 3.  Listeriosis: clinical presentation.

Authors:  Mehmet Doganay
Journal:  FEMS Immunol Med Microbiol       Date:  2003-04-01

4.  Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.

Authors:  Jean-François Dhainaut; S Betty Yan; Benjamin D Margolis; José A Lorente; James A Russell; Ross C Freebairn; Herbert D Spapen; Hanno Riess; Bruce Basson; Gerald Johnson; Gary T Kinasewitz
Journal:  Thromb Haemost       Date:  2003-10       Impact factor: 5.249

5.  Differential substrate and inhibitor profiles for human MASP-1 and MASP-2.

Authors:  Julia S Presanis; Krishnan Hajela; Géza Ambrus; Péter Gál; Robert B Sim
Journal:  Mol Immunol       Date:  2004-02       Impact factor: 4.407

6.  Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo.

Authors:  Matthew J Flick; XinLi Du; David P Witte; Markéta Jirousková; Dmitry A Soloviev; Steven J Busuttil; Edward F Plow; Jay L Degen
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 7.  Coagulopathy of sepsis.

Authors:  Carl-Erik Dempfle
Journal:  Thromb Haemost       Date:  2004-02       Impact factor: 5.249

8.  Two mechanisms for mannose-binding protein modulation of the activity of its associated serine proteases.

Authors:  Ce-Belle Chen; Russell Wallis
Journal:  J Biol Chem       Date:  2004-04-01       Impact factor: 5.157

Review 9.  Proteases of the complement system.

Authors:  R B Sim; S A Tsiftsoglou
Journal:  Biochem Soc Trans       Date:  2004-02       Impact factor: 5.407

10.  Fibrin-mediated protection against infection-stimulated immunopathology.

Authors:  Lawrence L Johnson; Kiera N Berggren; Frank M Szaba; Wangxue Chen; Stephen T Smiley
Journal:  J Exp Med       Date:  2003-03-10       Impact factor: 14.307

View more
  55 in total

1.  Mannose-binding lectin-the forgotten molecule?

Authors:  Michael Osthoff; George Trendelenburg; Damon P Eisen; Marten Trendelenburg
Journal:  Nat Med       Date:  2011-12-06       Impact factor: 53.440

Review 2.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

3.  Plasma levels of MASP-1, MASP-3 and MAp44 in patients with type 2 diabetes: influence of glycaemic control, body composition and polymorphisms in the MASP1 gene.

Authors:  S S Krogh; C B Holt; R Steffensen; K L Funck; P Høyem; E Laugesen; P L Poulsen; S Thiel; T K Hansen
Journal:  Clin Exp Immunol       Date:  2017-04-20       Impact factor: 4.330

Review 4.  Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control.

Authors:  Akitada Ichinose
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

Review 5.  Mannose-binding lectin and the balance between immune protection and complication.

Authors:  Kazue Takahashi
Journal:  Expert Rev Anti Infect Ther       Date:  2011-12       Impact factor: 5.091

6.  Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis.

Authors:  Laura R La Bonte; Vasile I Pavlov; Ying S Tan; Kazue Takahashi; Minoru Takahashi; Nirmal K Banda; Chenhui Zou; Teizo Fujita; Gregory L Stahl
Journal:  J Immunol       Date:  2011-12-12       Impact factor: 5.422

7.  Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis.

Authors:  Vasile I Pavlov; Mikkel-Ole Skjoedt; Ying Siow Tan; Anne Rosbjerg; Peter Garred; Gregory L Stahl
Journal:  Circulation       Date:  2012-10-02       Impact factor: 29.690

8.  Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model.

Authors:  Vasile I Pavlov; Ying S Tan; Erin E McClure; Laura R La Bonte; Chenhui Zou; William B Gorsuch; Gregory L Stahl
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

9.  Serum cytokines associated with severity and complications of kala-azar.

Authors:  Dorcas L Costa; Regina L Rocha; Rayssa M A Carvalho; Adelino S Lima-Neto; Michael O Harhay; Carlos Henrique N Costa; Manoel Barral-Neto; Aldina P Barral
Journal:  Pathog Glob Health       Date:  2013-03       Impact factor: 2.894

10.  Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases.

Authors:  V Frauenknecht; S Thiel; L Storm; N Meier; M Arnold; J-P Schmid; H Saner; V Schroeder
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.